Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REGN 7999

Drug Profile

REGN 7999

Alternative Names: REGN-7999

Latest Information Update: 23 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Monoclonal antibodies
  • Mechanism of Action TMPRSS6 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Iron overload
  • Preclinical Beta-thalassaemia

Most Recent Events

  • 20 May 2024 Regeneron Pharmaceuticals plans a phase II trial for Iron overload due to Beta thalassemia in September 2025 (SC) (NCT06421636) (EudraCT-2023-508604-37-00)
  • 09 Dec 2023 Pharmacokinetics and adverse events data from a phase I trial in Iron overload presented at the 65th American Society of Hematology Annual Meeting (ASH-2023)
  • 24 Aug 2023 Regeneron Pharmaceuticals completes a phase I trial for Iron overload (In volunteers) in Belgium (IV) (SC)(NCT05481333) (EudraCT2022-500398-15-00)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top